Abbvie Inc.

Galapagos Nv

Abbvie S.a.r.l.

Other

Abbott Laboratories Corporation

Calico Life Sciences LLC

Abbvie Overseas Sarl

Abbvie Global Enterprises Ltd.

Eric A Voight

Philip R Kym

Arthur Gomtsyan

Michael E Kort

Jerome F Daanen

Gregory A Gfesser

Erol K Bayburt

Robert G Schmidt

Michael J Dart

Kevin R Woller

Valentino J Stella

John T Randolph

John R Koenig

Peter T Mayer

Richard J Perner

Mark A Matulenko

Yanbin Lao

Stanley DiDomenico

Xiaochun Lou

Bruce Clapham

Ye Huang

Anurupa Shrestha

Sean E Mackey

Phil B Cox

Christopher P Miller

Heath A McDonald

Brian P Enright

Rolf Wagner

Robert J Altenbach

Allan C Krueger

David A DeGoey

Yi-Yin Ku

Ming Clinton Yeung

Bo Liu

Tongmei Li

Geoff G Zhang

Brian S Brown

Tammie K Jinkerson

Xenia Beebe Searle

Andrew Bogdan

Hui-Ju J Chen

Vincent S Chan

Ryan G Keddy

Stephen N Greszler

Jun Chen

Zhi Wang

Christopher C Marvin

John Hartung

Russell C Klix

Vikram Kalthod

James Patrick Stambuli

Geoff T Halvorsen

Benoit Cardinal-David

Alexander D Huters

Scott W Krabbe

Jaclyn Chau

Nathan Ide

Marlon D Cowart

Chih-hung Lee

Clara I Villamil

Xueqing Wang

Anil Vasudevan

Rodger F Henry

Jennifer M Frost

Sridhar Peddi

Irene I Drizin

Huaqing Liu

Karine Fabienne Malagu

Derek W Nelson

Sachin V Patel

Lei Shi

Yunsong Tong

Marina Pliushchev

Marc J Scanio

Howard Robin Heyman

Kathleen Mortell

Xiangdong Xu

Carmela Sidrauski

Raimundo Ho

Kathleen J Murauski

Kassibla E Dempah

Pamela S Puttfarcken

Steven R Martinez

William Ramesh Esmieu

Xeuquing Wang

Kathleen Ann Martin

James Stambuli

Arthur R Gomtsyan

Phil Kym

Chih-Hung Lee

Heath A Mcdonald

Michael R Kort

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Prodrug modulators of the integrated stress pathway

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Methods of treating Parkinson's disease

Carbidopa prodrug

Carbidopa and L-dopa prodrugs and methods of use

The present invention features compounds effective in inhibiting active against Hepatitis C virus ('HCV') polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

The present invention provides for compounds of formula (I) wherein X, Y, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted tricyclics and method of use

The invention provides for compounds of formula (I) wherein R, X, Y, R, R, R, R, R, R, R, R, R, R, R, m, and R&#x2033; have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted chromanes and method of use

Disclosed herein are modulators of TRPV3 of formula (I) wherein G, X, X, X, X, X, G, Z, R, R, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X, X, X, X, J, K, L, X, X, R, G, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X, L, R, R, R, R, R, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Growing community of inventors

Pleasant Prarie, WI, United States of America

Eric A Voight